David Richards emphasized the therapy’s potential to enhance antibiotic effectiveness by targeting bacterial biofilms, a significant challenge in treatment.
David Richards
Advertisement
CEO of Clarametyx Biosciences.
Articles by David Richards
Advertisement
Latest Updated Articles
Clarametyx Biosciences Initiates Phase 2a Trial for CMTX-101 in Cystic Fibrosis PatientsPublished: October 24th 2024 | Updated:
Advertisement
Advertisement
Trending on Contagion Live
1
Clinical Takeaways From ViiV’s PASO DOBLE and CLARITY Studies
2
Phage and Antibiotic Combination Therapy for Biofilm-Associated Bacterial Infections
3
Streamlining IV-to-Oral Transitions in Pneumonia Care: Duration, Tailoring, and Post-Discharge Considerations
4
WHO Calls for Global Action on Growing AMR
5
